Zobrazeno 41 - 50
of 264
pro vyhledávání: '"Ajjai Alva"'
Autor:
C.A. Schonewolf, Christopher D. Lao, Ajjai Alva, Xueting Lang, Ilona Kryczek, Fengyun Su, Jiali Yu, Alangoya Tezel, Yilun Sun, Kyle C. Cuneo, Arul M. Chinnaiyan, Meredith A. Morgan, Syed Monem Rizvi, Linda Vatan, Issam El Naqa, Rohan K. Achar, Shuang Wei, Charles S. Mayo, Theodore S. Lawrence, Long Jiang, Wojciech Szeliga, Zoey Chopra, Nithya Ramnath, Weiping Zou, Sara Journey, Jiajia Zhou, Marcin Cieslik, Vincent T. Ma, Jae Eun Choi, Jeremy Skvarce, Xuhong Cao, Shasha Li, Fei Wen, Jessica Waninger, Yingjie Bian, Merna Sitto, Michael D. Green, Angel Qin, B.S. Rosen, Sathiya Pandi Narayanan
Publikováno v:
Nature Medicine. 27:152-164
Metastasis is the primary cause of cancer mortality, and cancer frequently metastasizes to the liver. It is not clear whether liver immune tolerance mechanisms contribute to cancer outcomes. We report that liver metastases diminish immunotherapy effi
Autor:
Gaopeng Li, Jae Eun Choi, Ilona Kryczek, Yilun Sun, Peng Liao, Shasha Li, Shuang Wei, Sara Grove, Linda Vatan, Reagan Nelson, Grace Schaefer, Steven G. Allen, Kamya Sankar, Leslie A. Fecher, Mishal Mendiratta-Lala, Timothy L. Frankel, Angel Qin, Jessica J. Waninger, Alangoya Tezel, Ajjai Alva, Christopher D. Lao, Nithya Ramnath, Marcin Cieslik, Paul W. Harms, Michael D. Green, Arul M. Chinnaiyan, Weiping Zou
Publikováno v:
Cancer Cell. 41:304-322.e7
Autor:
Joaquin Mateo, Arul M. Chinnaiyan, William Oh, Maha Hussain, Nikolaus Schultz, Howard R. Soule, Eric J. Small, Rana R. McKay, Rahul Aggarwal, Wassim Abida, Fatima Karzai, David B. Solit, Eliezer M. Van Allen, Felix Y. Feng, Jake Vinson, Bruce Montgomery, Vaibhav G. Patel, Matthew R. Smith, David J. VanderWeele, Julie N. Graff, Himisha Beltran, William L. Dahut, Matthew Rettig, Dana E. Rathkopf, Andrea K. Miyahira, Ajjai Alva, Jonathan W. Simons, Cora N. Sternberg, Xin Gao, Joshi J. Alumkal
Publikováno v:
Nat Cancer
Nature cancer, vol 1, iss 11
Nature cancer, vol 1, iss 11
Despite advances in the screening and treatment of prostate cancer, the therapy options available, particularly for later stages of the disease, remain limited, and the treatment-resistant setting represents a serious unmet medical need. Moreover, di
Autor:
Umang Swami, Roberto Nussenzveig, John Esther, Ajjai Alva, Andrew W. Hahn, Stephanie Erickson, Neeraj Agarwal, Benjamin L. Maughan, Ulka N. Vaishampayan, Victor Sacristan Santos, Jonathan Chipman, Emmanuel S. Antonarakis, Divya Dharmaraj, Pedro Isaacsson Velho
Publikováno v:
Eur Urol
Recently, mutations in speckle-type pox virus and zinc finger protein (SPOP) gene (mutant SPOP [mtSPOP]) have been associated with improved outcomes to abiraterone in the castration-resistant setting. We hypothesized that mtSPOP would be associated w
Autor:
Brittany McCreery, Bryan Lewis, Naomi B. Haas, Lakshminarayanan Nandagopal, Mary A. Dwyer, Angela D. Motter, Christos Kyriakopoulos, Ajjai Alva, Maria I. Carlo, Phillip M. Pierorazio, M. Dror Michaelson, Sundhar Ramalingam, Brandon Manley, Clayton Lau, Lee Ponsky, Eric Jonasch, Neeraj Agarwal, David C. Madoff, Elizabeth R. Plimack, Bradley G. Somer, Jeffrey A. Sosman, Robert J. Motzer, Amir Mortazavi, Steven L. Hancock, Shawna L. Boyle, Elaine T. Lam, Ithaar Derweesh, Brian Shuch, Katy Beckermann, Arpita Desai, Saby George, Brian A. Costello, Zachary L. Smith, John L. Gore, Toni K. Choueiri
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:1160-1170
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, inclu
Autor:
Toni K. Choueiri, Howard Gurney, David F. McDermott, Christian Kollmannsberger, Michael A. Carducci, Martin Eduardo Richardet, M. Brent McHenry, Elizabeth R. Plimack, Fabio A.B. Schutz, David Cella, Nizar M. Tannir, Frede Donskov, Bernard Escudier, John Wagstaff, Yoshihiko Tomita, Robert J. Motzer, Satoshi Fukasawa, Shruti Shally Saggi, Saby George, Giuseppe Procopio, Christine Chevreau, Hans J. Hammers, Thomas Gauler, Daniel Castellano, Jeffrey A. Sosman, James Larkin, Ajjai Alva, Sandhya Srinivas, Katriina Peltola, Scott S. Tykodi, Stéphane Oudard
Publikováno v:
Cancer
Motzer, R J, Escudier, B, George, S, Hammers, H J, Srinivas, S, Tykodi, S S, Sosman, J A, Plimack, E R, Procopio, G, McDermott, D F, Castellano, D, Choueiri, T K, Donskov, F, Gurney, H, Oudard, S, Richardet, M, Peltola, K, Alva, A S, Carducci, M, Wagstaff, J, Chevreau, C, Fukasawa, S, Tomita, Y, Gauler, T C, Kollmannsberger, C K, Schutz, F A, Larkin, J, Cella, D, McHenry, M B, Saggi, S S & Tannir, N M 2020, ' Nivolumab versus everolimus in patients with advanced renal cell carcinoma : Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial ', Cancer, vol. 126, no. 18, pp. 4156-4167 . https://doi.org/10.1002/cncr.33033
Motzer, R J, Escudier, B, George, S, Hammers, H J, Srinivas, S, Tykodi, S S, Sosman, J A, Plimack, E R, Procopio, G, McDermott, D F, Castellano, D, Choueiri, T K, Donskov, F, Gurney, H, Oudard, S, Richardet, M, Peltola, K, Alva, A S, Carducci, M, Wagstaff, J, Chevreau, C, Fukasawa, S, Tomita, Y, Gauler, T C, Kollmannsberger, C K, Schutz, F A, Larkin, J, Cella, D, McHenry, M B, Saggi, S S & Tannir, N M 2020, ' Nivolumab versus everolimus in patients with advanced renal cell carcinoma : Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial ', Cancer, vol. 126, no. 18, pp. 4156-4167 . https://doi.org/10.1002/cncr.33033
Background: CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab
Autor:
Linda Karpiak, Matthew H. Taylor, Sebastian Szpakowski, Alpesh Amin, Sarina Anne Piha-Paul, Das Purkaystha, Ajjai Alva, Timothy Larson
Publikováno v:
Oncotarget
// Matthew H. Taylor 1 , Ajjai S. Alva 2 , Timothy Larson 3 , Sebastian Szpakowski 4 , Das Purkaystha 5 , Alpesh Amin 5 , Linda Karpiak 5 and Sarina A. Piha-Paul 6 1 Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health
Autor:
Kimberly L. Shampain, Prasad R. Shankar, Kenny H. Cha, Alon Z. Weizer, Galina Kirova-Nedyalkova, Heang Ping Chan, Phillip L. Palmbos, Lubomir M. Hadjiiski, Ravi K. Samala, Nathaniel B. Meyer, Daniel Barkmeier, Sean Woolen, Isaac R. Francis, Elaine M. Caoili, Ajjai Alva, Richard H. Cohan, Matthew S. Davenport
Publikováno v:
Acad Radiol
Rationale and Objectives To evaluate whether a computed tomography (CT)-based computerized decision-support system for muscle-invasive bladder cancer treatment response assessment (CDSS-T) can improve identification of patients who have responded com
Autor:
Leonard Joseph Appleman, Lawrence Fong, Daniel P. Petrylak, Raphaelle Porcu, Ulka N. Vaishampayan, Andrew J. Armstrong, Darren Tayama, Celestia S. Higano, Kobe C. Yuen, Lance C. Pagliaro, Asim Datye, Winston Tan, Edward E. Kadel, Ajjai Alva, Oliver Sartor, Michael J. Morris
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 17
Clin Cancer Res
Clin Cancer Res
Purpose:Men with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options after progressing on hormonal therapy and chemotherapy. Here, we evaluate the safety and efficacy of atezolizumab (anti–PD-L1) + radium-223 dich
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a31d073a659b299e25ab04ad70f292b3
https://escholarship.org/uc/item/5km9c6ps
https://escholarship.org/uc/item/5km9c6ps
Autor:
Michael J. Morris, Ajjai Alva, Steven P. Rowe, Kenneth J. Pienta, Peter R. Carroll, Barry A. Siegel, Nancy Stambler, Akash Patnaik, Lawrence Saperstein, Stephan Probst, Michael A. Gorin, Frédéric Pouliot, Mark A. Preston
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Several PSMA-targeted imaging agents are currently in development for initial staging of men at risk of harboring metastatic prostate cancer (PCa) not detected by convent...